| 发明名称 |
METHOD OF ADMINISTRATION AND TREATMENT |
| 摘要 |
The present invention is directed to methods of administering foretinib or pharmaceutically acceptable salts or solvates thereof a c-Met inhibitor to a patient in need thereof comprising:
determining whether said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene; andif said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene, administering to said patient a pharmaceutical composition comprising foretinib or a pharmaceutically acceptable salt thereof. |
| 申请公布号 |
US2014221372(A1) |
申请公布日期 |
2014.08.07 |
| 申请号 |
US201414173973 |
申请日期 |
2014.02.06 |
| 申请人 |
GlaxoSmithKline Intellectual Property (NO 2.) Limited |
发明人 |
KULKARNI Diptee Amit;Spraggs Colin F |
| 分类号 |
A61K31/5377 |
主分类号 |
A61K31/5377 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating cancer in a patient in need thereof comprising:
determining whether said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene; and if said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene, administering to said patient a c-Met inhibitor. |
| 地址 |
Brentford GB |
